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Abstract
Introduction: Systemic Epstein-Barr-virus-positive T cell lymphoproliferative disease of childhood is an extremely
rare disorder, characterized by clonal proliferation of Epstein-Barr-virus-infected T cells with an activated cytotoxic
phenotype. The disease is more frequent in Asia and South America, with only few cases reported in Western
countries. A prompt diagnosis, though often difficult, is a necessity due to the very aggressive clinical course of the
disease.
Case presentation: We report the clinicopathological features of fulminant T cell lymphoproliferative disease that
arose in the setting of acute primary Epstein-Barr virus infection. Our patient, a 23-year-old man, presented to our
facility with persisting fever, hepatosplenomegaly and severe pancytopenia. On bone marrow biopsy, an abundant
lymphoid infiltrate was observed. Immunophenotypic and molecular studies revealed that the atypical lymphoid
cells displayed a CD8+, Epstein-Barr-encoded-RNA-positive T cell phenotype with clonal rearrangement of the T cell
receptor genes, the final diagnosis being systemic Epstein-Barr-virus-positive T cell lymphoproliferative disease. On
reviewing the literature we found only 14 similar cases, all presenting with very aggressive clinical courses and
requiring extensive phenotyping and molecular techniques for final diagnosis.
Conclusion: Though extremely rare, this disease can occur in Europe, and a comprehensive diagnostic approach is
thus recommended in all case of Epstein-Barr-virus-positive lymphoproliferative disorders. Unfortunately, at present
no specific treatment is available; however, prompt administration of anti- Epstein-Barr virus treatment and rapid
attempts to control the hemophagocytic syndrome are indicated.
Introduction
Primary infection of Epstein-Barr virus (EBV) is com-
monly asymptomatic, but some children, adolescents and
young adults develop infectious mononucleosis [1] (IM),
a benign febrile disease characterized by hepatospleno-
megaly, lymphadenopathy, and increase of activated CD8
+ T lymphocytes in peripheral blood [1,2]. However,
exceptionally, younger patients can develop a very
aggressive form, referred to in the past as ‘fulminant
infectious mononucleosis’ or ‘fatal haemophagocytic syn-
drome’. The disorder is characterized by rapid deteriora-
tion in previously healthy children, secondary to acute
primary EBV infection; this syndrome is accompanied by
high fever, skin rash, pulmonary infiltrate, jaundice, hepa-
tosplenomegaly, cytopenia, haemophagocytic syndrome,
and coagulopathy [3]. Unfortunately, patients commonly
die within a few weeks of diagnosis.
In addition, EBV is implicated in the pathogenesis of
different types of lymphoproliferative diseases (LPD),
which are related to diverse immune alterations or
peculiar clinical backgrounds [4]. Typically, EBV-asso-
ciated lymphoproliferative disorders are derived from B
cells, such as Hodgkin disease and Burkitt lymphoma,
* Correspondence: pierpaolo.piccaluga@unibo.it
1Department of Hematology and Oncological Sciences ‘L and A Seràgnoli’,
Hematopathology Section, S Orsola-Malpighi Hospital, University of Bologna,
Bologna, Italy
Full list of author information is available at the end of the article
Tabanelli et al. Journal of Medical Case Reports 2011, 5:218
http://www.jmedicalcasereports.com/content/5/1/218 JOURNAL OF MEDICAL
CASE REPORTS
© 2011 Tabanelli et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
where memory B cells are the physiological reservoir of
latent EBV [1]. Nonetheless, rare EBV-driven T cell
tumors have been recognized.
In this regard, fulminant mononucleosis has recently been
demonstrated to be a monoclonal CD8+ LPD, and is cur-
rently classified as systemic EBV+ T cell LPD of childhood
in the World Health Organization classification of tumors
of hematopoietic and lymphoid tissues [5]. This entity is a
rare clonal proliferation of EBV-infected T cells with an
activated cytotoxic phenotype [5]; the disease occurs with
increased frequency in immunocompetent children and
young adults, appears to be more common in Asians and
Native Americans, and is associated with rapid progression,
high morbidity and mortality. It can develop after primary
EBV infection or in association with chronic active EBV
infection (CAEBV). Despite the name, the disease occurs
not only in children but in adolescent and young adults as
well, the median age being around 20 years [5].
At morphology, neoplastic T cells are usually small and
lack significant cytological atypia [6]. However, cases
with pleomorphic medium-sized to large-sized lymphoid
cells, irregular nuclei and frequent mitoses have been
described. The most typical phenotype is CD2+, CD3+,
CD8+, CD56-, and TIA+ [6-8]; conversely, cases arising in
the setting of severe CAEBV are CD4+. Neoplastic cells
have monoclonally rearranged T cell receptor (TCR)
genes, and consistent Epstein-Barr encoded RNA (EBER)
positivity at in situ hybridization (ISH). Differential diag-
nosis mainly concerns reactive conditions as well as
aggressive natural killer (NK) cell leukemia.
Here, we report the clinicopathological features of ful-
minant T-LPD that arose in the setting of acute primary
EBV infection in our patient, characterized by a mono-
clonal proliferation of EBV-infected T cells.
Case presentation
A 23-year-old Caucasian man was hospitalized for per-
sisting fever resistant to conventional therapies. On phy-
sical examination, our patient presented with marked
hepatosplenomegaly and abnormal sounds at thoracic
auscultation. Laboratory findings consisted of severe
pancytopenia (hemoglobin 9.3 g/dL, platelets 93 × 109
cells/L, white blood cells 2.2 × 109 cells/L, neutrophils
410 × 109 cells/L, lymphocytes 1.570 × 109 cells/L),
increased LDH, signs of disseminated intra-vascular coa-
gulopathy (CID), and anti-EBV IgM positivity, while a
chest X-ray showed diffuse pulmonary infiltrates. No
prior immunological abnormalities were recorded.
For the suspicion of either massive bone marrow infil-
tration by leukemia/lymphoma or hemophagocytic syn-
drome a bone marrow biopsy was performed. Results
from the biopsy showed the bone marrow was hypercel-
lular, with numerous atypical lymphoid cells and occa-
sional hemophagocytes (identified by positive staining
for CD68/PGM1) (Figure 1). Lymphocytes were more
often small and without significant atypia; a smaller per-
centage was represented by larger cells (Figures 1
and 2). Immunohistochemistry (IHC) investigation
results showed atypical lymphocytes were CD79a-,
CD3+, CD2+, CD8+ and TIA1+ (Figure 2). ISH for EBER
demonstrated that the majority of lymphoid cells were
positive (Figure 2). Finally, polymerase chain reaction
(PCR) analysis revealed a monoclonal rearrangement of
the TCRg genes. IHC, ISH and molecular analyses were
carried out as previously described [9,10].
Based on the above findings, a final diagnosis of sys-
temic EBV+ T cell LPD of childhood was made. Our
patient was initially treated with two sequential doses of
VP16 with moderate improvement of his clinical and
laboratory data. In particular, the fever transiently
improved, hepatosplenomegaly was reduced, and coagu-
lation parameters were partially corrected; however,
severe peripheral blood cytopenia persisted. Soon after,
the patient developed a fever recrudescence in associa-
tion with pulmonary fungal infection.
Figure 1 Pathological findings on lymph node biopsy. Giemsa,
Ki67 and CD68 immunostains are shown. Arrows indicate atypical
cells (GM) as well as eritrophagocytic syndrome (CD68).
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A second bone marrow biopsy was performed, reveal-
ing (hypo)aplasia with a minimum percentage of CD79a-
, CD3+, CD4-, CD8+, EBER- small lymphocytes and
absence of the previously observed CD8+ large cells.
VP16 was then replaced with cyclosporine, obtaining a
white blood cell count increase and a further decline of
splenomegaly, but with no improvement in thrombocy-
topenia. A third bone marrow biopsy showed an
increased cellularity with reappearance of numerous
CD8+ lymphocytes and evident hemophagocytosis.
Our patient then developed rectal hemorrhages only
treatable with surgery, which turned out to be sustained
by microvascular thrombosis on histological examina-
tion. Finally, after a short period of relative good health,
our patient had a relapse of rectal bleeding and died
soon after with cerebral manifestations.
Discussion
Systemic EBV+ T cell LPD of childhood is a rare disor-
der characterized by an aggressive disease course and
dismal prognosis [5]. As death unfortunately often
occurs within a few weeks, and at present there is no
specific treatment, a prompt diagnosis is necessary. Our
case report highlights the fact that, though rare, such a
disease can occur also in Europe.
On reviewing the literature, we found only 14 cases
reported in Western countries [6,11-14], specifically
cases recorded in Europe and the USA (Table 1). Inter-
estingly, the majority of cases have been reported in
eastern Asia [5], specifically in Japan and Taiwan. The
geographical distribution has been suggested to indicate
possible genetically determined defects in T cell
responses to EBV in certain populations.
Our review of Western cases showed that four of
those 14 patients developed a T cell LPD after CAEBV
infection [6,11], and 10 presented a fulminant EBV T
cell LPD following acute EBV infection. In the former
group, ethnic origin was specified only in one case
(white); in the latter group, one patient was of Cauca-
sian descent, four were Asian or Native American, while
in five cases the ethnic group was not specified. Mean
age at onset was 17 years and the male/female ratio was
2.3:1. Common symptoms were fever, hepatosplenome-
galy and hematophagocytic syndrome; the clinical
courses were fulminant in patients with T cell LPD after
acute IM. In particular, in the acute IM group three
cases had a CD8+ phenotype, two a CD4+ phenotype
and one showed double positivity for CD8 and CD4; in
one case phenotype was not interpretable and in three
cases it was not reported. TCRa presented with clonal
rearrangements in nine out of 10 patients and EBV gen-
ome was clonal in all but one case. In contrast, among
patients with T cell LPD after CAEBV infection two
were CD4+, one was CD45RO+ and one presented with
an admixture of CD8+ and CD4+ lymphocytes; three
cases presented with monoclonal patterns with regard to
rearrangement of both TCRa genes and EBV genome.
In the remaining case, only the EBV positivity was
assessed.
In all described cases, an accurate diagnostic investiga-
tion including clinical, morphological, immunohisto-
chemical, and molecular analyses was necessary in order
to formulate a correct diagnosis. In particular, the differ-
ential diagnosis with aggressive NK cell leukemia was
based on surface sCD3 and CD8 positivity, CD56 nega-
tivity, and evidence of TCRa rearrangement in systemic
EBV+ T cell LPDs, and also sCD3/CD8 negativity, CD56
positivity and germline TCRa patterns in aggressive NK
cell leukemia cases.
Conclusion
In conclusion, our case report underlines the impor-
tance of a comprehensive diagnostic approach in the
management of atypical EBV+ LPDs. In fact, though, at
present, specific therapies are not available, the correct
Figure 2 Pathological findings on lymph node biopsy. CD3,
CD8, CD56, TIA1 immunostains and Epstein-Barr encoded RNA
(EBER) in situ hybridization are shown.
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description of rare disorders is essential for improving
current knowledge and possibly future therapeutic
approaches.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompany-
ing images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
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Table 1 Cases of systemic Epstein-Barr virus positive (EBV+) T cell lymphoproliferative disease (LPD) of childhood
described in Western countries
Reference Age/
sex










two/M Unspecified Fever, generalized erythematous skin eruption,
hepatosplenomegaly, pancytopenia, hypoplastic
bone marrow, pulmonary infiltrates

















55/M Unspecified Gluten enteropathy for 19 years; fever, persistent
diarrhea, nodular erythematous skin lesion






seven/F Unspecified Infectious acute mononucleosis, persistent high-
grade fever, weight loss, adenopathy, necrotizing
skin lesions and VAHS
four
months










Unspecified Fever, generalized erythematous skin eruption,
hepatosplenomegaly










37/M White Fever, mental status of one week duration,
hepatosplenomegaly, pancytopenia, jaundice









Symptoms of viral upper respiratory illness,
hepatosplenomegaly, pancytopenia, jaundice







23/M Asian Fever, night sweats, weight loss,
hepatosplenomegaly, pancytopenia, jaundice,
generalized lymphadenopathy



















Fever, skin rash, hepatosplenomegaly,
pancytopenia







15/F White IM at eight years old, followed by CAEBV. At 14
years old developed hepatosplenomegaly and
hemophagocytic syndrome.






























CAEBV = chronic active EBV infevtion; FIM = fatal infectious mononucleosis; HLA = human leukocyte antigen; IM = infectious mononucleosis; NOS = not
otherwise specified; TCR = T cell receptor; VAHS = virus-associated hemophagocytic syndrome.
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